A5087887033- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- Cancer Genomics and Diagnostics
- Interpreting and Communication in Healthcare
- Pharmaceutical industry and healthcare
- Biomedical Ethics and Regulation
- Ethics in Clinical Research
- Lung Cancer Research Studies
- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- Neuroendocrine Tumor Research Advances
- Chemokine receptors and signaling
- vaccines and immunoinformatics approaches
Western University of Health Sciences
2023
University of California, Los Angeles
2020-2023
UCLA Health
2020
Abstract Immune check point blockade (ICB) has recently transformed the treatment of non-small cell lung (NSCLC). However, majority patients do not respond to ICB. For ICB be effective, tumor neoantigens need presented in a human leukocyte antigen (HLA) class I-restricted manner. Recent studies by our group and others have shown that HLA-B44 supertype is associated with extended survival treated Herein, we hypothesize HLA-B44-specific motif neoepitopes generate an active immune...
3083 Background: Recent evidence suggests efficacy of immune checkpoint blockade may be influenced by human leukocyte antigen (HLA)-B. HLA-B27 supertype has an electronegative binding pocket which favorably binds and displays neoepitopes harboring positively charged amino acids (AAs). Based on surveillance, we postulate that B27 tumors have favorable should face negative selective pressure, with develop could more likely to upregulate escape mechanisms. Here evaluate the relationship between...
Abstract Purpose: Immune checkpoint blockade (ICB) has revolutionized treatment of melanoma and lung cancer. Recent evidence suggests that human leukocyte antigen (HLA) B supertype influences efficacy ICB. HLA-B27 B44 supertypes have electronegative electropositive binding pockets, respectively, preferentially bind display oppositely charged neoepitopes. We sought to evaluate the relationship between baseline immune activation neoepitopes in context HLA-B pockets. Methods: Datasets from a...
Abstract Programmed death (ligand) 1 checkpoint inhibitors have become standard treatment in patients with non–small cell lung cancer. Recently, combinations of nivolumab and ipilimumab entered the clinic based on regulatory approval. Oftentimes, these are given conjunction chemotherapy. Through increased understanding evasion by cancer cells, many promising studies using combination therapies continued to develop that aim attack cells eliciting immunogenic responses through different...
Abstract Patients from historically underrepresented racial and ethnic groups are enrolled in cancer clinical trials at disproportionately low rates the United States 1-3 . As these patients often have limited English proficiency 4-7 , we hypothesized that one barrier to their inclusion is cost investigators of translating consent documents. To test this hypothesis, evaluated more than twelve-thousand events a large Cancer Center assessed whether requiring translated documents would sign...